Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry

Evaluation of the Feasibility and Efficacy of Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma

(2014) Tsuyoshi Muta et al.   INTERNAL MEDICINE

Validation of the Freiburg Comorbidity Index in 466 Multiple Myeloma Patients and Combination With the International Staging System Are Highly Predictive for Outcome

(2013) Martina Kleber et al.   Clinical Lymphoma Myeloma & Leukemia

Personal Financial Effects of Multiple Myeloma and Its Treatment

(2012) Julia A. Goodwin et al.   CANCER NURSING

Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial

(2012) Michel Delforge et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry

(2012) Floortje Mols et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

(2012) M. A. Dimopoulos et al.   HAEMATOLOGICA

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

(2012) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial

(2011) Silvia G. R. Verelst et al.   ANNALS OF HEMATOLOGY

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

(2011) P. M. Fayers et al.   BLOOD

The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: Scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts

(2011) Lonneke V. van de Poll-Franse et al.   EUROPEAN JOURNAL OF CANCER

Socio-economic implications of cancer survivorship: Results from the PROFILES registry

(2011) Floortje Mols et al.   EUROPEAN JOURNAL OF CANCER

Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM–comorbidity score

(2011) M Kleber et al.   Blood Cancer Journal

Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population

(2010) Lonneke V. van de Poll-Franse et al.   EUROPEAN JOURNAL OF CANCER

Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study

(2010) Pierre Wijermans et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

(2010) Maria-Victoria Mateos et al.   JOURNAL OF CLINICAL ONCOLOGY

Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

(2010) Kim Cocks et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial

(2009) Cyrille Hulin et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE